403 related articles for article (PubMed ID: 24343986)
1. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
2. Carbidopa-assisted
Helali M; Addeo P; Heimburger C; Detour J; Goichot B; Bachellier P; Namer IJ; Taïeb D; Imperiale A
Ann Nucl Med; 2016 Nov; 30(9):659-668. PubMed ID: 27485404
[TBL] [Abstract][Full Text] [Related]
3. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
4. Limited role of carbidopa-assisted
Imperiale A; Averous G; Helali M; Taieb D; Pessaux P; Goichot B; Addeo P; Bachellier P
Ann Nucl Med; 2019 Sep; 33(9):697-707. PubMed ID: 31214959
[TBL] [Abstract][Full Text] [Related]
5. The Added Diagnostic Value of
Addeo P; Poncet G; Goichot B; Leclerc L; Brigand C; Mutter D; Romain B; Namer IJ; Bachellier P; Imperiale A
J Gastrointest Surg; 2018 Apr; 22(4):722-730. PubMed ID: 29235002
[TBL] [Abstract][Full Text] [Related]
6. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
Montravers F; Grahek D; Kerrou K; Ruszniewski P; de Beco V; Aide N; Gutman F; Grangé JD; Lotz JP; Talbot JN
J Nucl Med; 2006 Sep; 47(9):1455-62. PubMed ID: 16954553
[TBL] [Abstract][Full Text] [Related]
7. PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting.
Yakemchuk VN; Jager PL; Chirakal R; Reid R; Major P; Gulenchyn KY
Nucl Med Commun; 2012 Mar; 33(3):322-30. PubMed ID: 22183015
[TBL] [Abstract][Full Text] [Related]
8. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
9. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
10. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
12. Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients.
Noordzij W; van Beek AP; Tio RA; van der Horst-Schrivers AN; de Vries EG; van Ginkel B; Walenkamp AM; Glaudemans AW; Slart RH; Dierckx RA
PLoS One; 2014; 9(11):e112278. PubMed ID: 25397775
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
Jullien M; Reichert T; D'Anella P; Castinetti F; Barlier A; Brue T; Taieb D; Cuny T
Ann Endocrinol (Paris); 2020 Feb; 81(1):39-43. PubMed ID: 31982106
[TBL] [Abstract][Full Text] [Related]
14. Terminal ileum neuroendocrine incidentaloma in a patient with sporadic medullary thyroid carcinoma: findings from 18F-FDOPA PET/CT investigation.
Imperiale A; Rust E; Boulanger C; Roedlich MN; Ollier JC; Schneegans O
Clin Nucl Med; 2012 Aug; 37(8):e206-8. PubMed ID: 22785529
[TBL] [Abstract][Full Text] [Related]
15. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data.
Talbot JN; Kerrou K; Missoum F; Grahek D; Aide N; Lumbroso J; Montravers F
Mol Imaging Biol; 2005; 7(4):257-61. PubMed ID: 16082495
[TBL] [Abstract][Full Text] [Related]
16. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDOPA PET/CT imaging of insulinoma revisited.
Imperiale A; Sebag F; Vix M; Castinetti F; Kessler L; Moreau F; Bachellier P; Guillet B; Namer IJ; Mundler O; Taïeb D
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):409-18. PubMed ID: 25367749
[TBL] [Abstract][Full Text] [Related]
18. Characterization of neuroblastic tumors using 18F-FDOPA PET.
Lu MY; Liu YL; Chang HH; Jou ST; Yang YL; Lin KH; Lin DT; Lee YL; Lee H; Wu PY; Luo TY; Shen LH; Huang SF; Liao YF; Hsu WM; Tzen KY;
J Nucl Med; 2013 Jan; 54(1):42-9. PubMed ID: 23213196
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous (18)F-FDOPA PET/CT-guided biopsy and radiofrequency ablation of recurrent neuroendocrine hepatic metastasis: further step toward a theranostic approach.
Imperiale A; Garnon J; Bachellier P; Gangi A; Namer IJ
Clin Nucl Med; 2015 Jun; 40(6):e334-5. PubMed ID: 25706791
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome.
Weisbrod AB; Kitano M; Gesuwan K; Millo C; Herscovitch P; Nilubol N; Linehan WM; Kebebew E
J Clin Endocrinol Metab; 2012 Apr; 97(4):E613-7. PubMed ID: 22259055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
